Triple Incretin Agonist

Retatrutide

GLP-1 / GIP / Glucagon Receptor Agonist

Retatrutide is an investigational peptide designed to activate GLP-1, GIP, and glucagon receptors at the same time. This triple agonist approach targets appetite, blood sugar control, energy expenditure, and fat metabolism through multiple pathways.

Weight Loss Appetite Control Fat Oxidation Metabolic Health

Protocol Snapshot

Retatrutide Quick Reference

Verified Vendors

Retatrutide

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Community Start

0.5mg

Once weekly to assess response and tolerance

Titration Interval

4+ weeks

Increase only when additional effect is needed

Class

Triple Agonist

GIP, GLP-1, and glucagon receptors

Community Maintenance

~1mg or less

Commonly discussed after reaching the desired result

Peptide Grade

GradeA

TRIUMPH-1 reported 28.3% average weight loss at 80 weeks with 12mg, supported by randomized Phase 2 data and a published Phase 3 diabetes trial. The main limits are investigational status, dose-related gastrointestinal effects and dysesthesia, and the absence of long-term real-world safety data.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Retatrutide?

Retatrutide (LY3437943), often shortened to RETA or called “Triple G,” is a single peptide engineered to activate the GIP, GLP-1, and glucagon receptors. Eli Lilly is developing it as a once-weekly subcutaneous treatment for obesity, type 2 diabetes, and related metabolic conditions.

GLP-1 GIP Glucagon

Semaglutide primarily targets GLP-1, while tirzepatide targets GIP and GLP-1. Retatrutide adds glucagon-receptor activity to those two incretin pathways, creating a distinct balance of appetite, glucose, and energy-expenditure signaling.

The addition of glucagon receptor activity appears to increase energy expenditure and fat utilization, which may explain why Retatrutide has produced some of the largest weight loss results reported in obesity medicine.

Current Phase 3 Results

In TRANSCEND-T2D-1, adults with type 2 diabetes receiving 12mg lost an average of 16.8% at 40 weeks using the efficacy estimand. In TRIUMPH-1, adults with obesity or overweight receiving 12mg lost an average of 28.3% at 80 weeks, and 45.3% achieved at least 30% weight loss.

Benefits & Clinical Evidence

Significant Weight Loss

TRIUMPH-1 topline results reported 19.0%, 25.9%, and 28.3% average weight loss at 80 weeks with 4mg, 9mg, and 12mg, respectively.

Appetite Suppression

Community researchers frequently report major reductions in hunger, cravings, meal size, and persistent thoughts about food.

Blood Sugar Control

Published Phase 3 results showed average A1C reductions of 1.69–1.94 percentage points at 40 weeks across the 4–12mg groups.

Waist Reduction

TRIUMPH-1 reported dose-dependent reductions in waist circumference, reaching an average reduction of 24.1cm with 12mg at 80 weeks.

Cardiometabolic Health

Clinical research reported improvements in non-HDL cholesterol, triglycerides, systolic blood pressure, and hsCRP.

Liver-Fat Reduction

A Phase 2 substudy in participants with metabolic dysfunction-associated steatotic liver disease found large reductions in liver fat, supporting continued study in metabolic liver disease.

Mechanism of Action

GLP-1

Supports satiety, reduces energy intake, slows gastric emptying, and improves glucose-dependent insulin secretion.

GIP

Adds glucose-dependent insulin signaling and contributes to the combined metabolic effect of the molecule.

Glucagon

Adds a pathway associated with increased energy expenditure and lipid metabolism, while the GLP-1 and GIP components help balance glucagon’s glucose-raising potential.

Retatrutide vs. Tirzepatide

Tirzepatide targets GIP and GLP-1. Retatrutide adds glucagon-receptor activity, but no completed head-to-head trial has yet established comparative efficacy or safety.

Protocol Planning

Trial dosing, community context, and preparation

Retatrutide Dosing Context

There is no FDA-approved retatrutide dose. The clearest evidence comes from controlled clinical-trial schedules, which should be kept separate from lower-dose community protocols circulating online.

TRIUMPH-1 Phase 3 Schedule

Start

2mg once weekly

Escalate

Every 4 weeks

4mg Arm

2mg → 4mg

9mg Arm

2mg → 4mg → 6mg → 9mg

12mg Arm

2mg → 4mg → 6mg → 9mg → 12mg

Community Lower-Dose Context

Start

0.5mg weekly is commonly discussed to assess tolerance

Next Steps

1mg, 2mg, then 4mg are often discussed at intervals of at least 4 weeks

Escalate If

Appetite or weight response is inadequate and side effects remain tolerable

Hold If

Weight loss continues or nausea, vomiting, diarrhea, constipation, fatigue, or dysesthesia is limiting

Evidence

This lower-dose sequence is community practice, not a validated trial regimen

The Phase 3 target doses were 4mg, 9mg, and 12mg—not a general instruction to reach the highest dose. TRIUMPH-1 produced 19.0% average weight loss at 4mg with fewer adverse-event discontinuations than the 12mg arm.

Lowest Effective Dose Wins

The goal is not to reach the highest dose possible. The goal is to achieve the desired results on the lowest effective dose. If appetite control, weight loss, and metabolic improvements are occurring at a lower dose, there is often little reason to escalate further. Lower doses generally produce fewer side effects and better long-term tolerability.

Duration & Maintenance

Pattern

Retatrutide is generally approached as continuous once-weekly use rather than a short on-and-off cycle

After Goal

Community researchers commonly titrate downward instead of stopping and restarting

Maintenance

Around 1mg weekly or less is commonly discussed in the RUO community

Adjust

Use the lowest amount that maintains the desired appetite and weight response

Evidence

This maintenance approach reflects community practice; a validated maintenance dose has not been established

Retatrutide Reconstitution

10mg Vial

BAC Water

1mL

Concentration

10mg/mL

1mg

10 units on a U-100 syringe

4mg

40 units on a U-100 syringe

Reconstitution Calculator

Handling Notes

Mixing

Add bacteriostatic water slowly down the vial wall

Do Not

Shake aggressively

Storage

Refrigerate after reconstitution and do not freeze

Inspect

Discard if the solution becomes cloudy or contains visible particles

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

A dramatic reduction in cravings and persistent thoughts about food is among the most consistently reported effects.
Many users who have tried both compounds describe stronger appetite suppression and faster weight loss than with tirzepatide.
Some users describe steadier appetite control across the full week with fewer late-week hunger rebounds.
Some report better perceived energy than on other incretin-based compounds, particularly when calorie intake remains adequate.

Negative Reports

Nausea, diarrhea, constipation, reflux, or vomiting frequently worsen after dose increases; tolerance may improve after holding a stable dose.
Faster escalation is commonly associated with more side effects and difficulty eating enough protein or drinking enough fluid.
Some users report feeling colder than usual, fatigued, or lightheaded when weight loss or calorie restriction becomes aggressive.
Tingling, burning, or unusual skin sensitivity is a recurring complaint consistent with the dysesthesia signal reported in trials.

Stacking & Synergy

Potential Retatrutide pairings and tracking context

Retatrutide + 5-Amino-1MQ

May provide complementary support for body composition by combining appetite suppression with pathways involved in fat metabolism.

Retatrutide + AOD-9604

Often used by individuals focused on body fat reduction while trying to preserve lean mass.

Retatrutide + MOTS-c

Combines powerful weight loss effects with mitochondrial and metabolic support. MOTS-c is most often positioned as an energy, AMPK, and performance-support adjunct during aggressive fat-loss phases.

Retatrutide + Cagrilintide

Cagrilintide is an amylin analog that can complement Retatrutide by adding a separate satiety pathway. Retatrutide targets GLP-1, GIP, and glucagon signaling, while Cagrilintide may further reduce appetite, meal size, and food noise through amylin-mediated fullness.

Retatrutide + Tesamorelin

Visceral Fat Targeting: Tesamorelin is frequently stacked with Reta during aggressive fat-loss protocols to specifically reduce stubborn visceral abdominal fat while utilizing Reta for broader systemic appetite and metabolic regulation.

Retatrutide + Resistance Training

One of the most important combinations for preserving muscle mass during significant weight loss.

Free with login

Track in Journal

Track Retatrutide with the markers that matter most for this compound.

Weekly weight and waist trend.
Appetite, food noise, and protein intake.
GI symptoms, hydration, and dysesthesia.

Start Tracking

Common Questions

Clarifying the most common Retatrutide questions

How is Retatrutide different from Tirzepatide?

Tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon-receptor activity. A direct Phase 3 comparison is underway, but no completed head-to-head result is available.

Is 0.5mg a clinical-trial starting dose?

Not in the current Phase 3 programs. TRIUMPH-1 and TRANSCEND-T2D-1 started at 2mg weekly; 0.5mg is a community lower-dose practice.

Does everyone need to reach 12mg?

No. TRIUMPH-1 reported 19.0% average weight loss at 80 weeks with 4mg. Higher targets produced more weight loss but also more gastrointestinal effects and treatment discontinuations.

What is dysesthesia?

Dysesthesia means altered or unpleasant sensation, often described as tingling, burning, tenderness, or unusual skin sensitivity. It was dose-related in TRIUMPH-1.

Safety Notes

Side effects, contraindications, and precautions

Retatrutide Side Effects

Gastrointestinal effects remain the dominant tolerability issue and occur most often during dose escalation. TRIUMPH-1 also confirmed a dose-related dysesthesia signal that deserves more attention than it typically receives in community discussions.

At 12mg in TRIUMPH-1, 11.3% discontinued because of adverse events, compared with 4.1% at 4mg and 4.9% with placebo. Higher dose did not mean better tolerability.

TRIUMPH-1 at 12mg

Nausea: 42.4%
Diarrhea: 32.0%
Constipation: 26.1%
Vomiting: 25.3%

Important Additional Signals

Dysesthesia: 12.5% at 12mg versus 0.9% with placebo.
Small increases in resting heart rate were observed in earlier trials.
Persistent vomiting or diarrhea can cause dehydration and electrolyte disturbance.
Rapid weight loss and severe abdominal symptoms require evaluation for gallbladder or pancreatic complications.

When Symptoms Are Not Routine

Severe or persistent abdominal pain, repeated vomiting, inability to maintain fluids, fainting, or symptoms of an allergic reaction are not ordinary titration effects and warrant prompt medical evaluation.

Trial Exclusions & Major Precautions

Retatrutide has no approved prescribing label, so it does not yet have FDA-defined contraindications. The Phase 3 obesity trial excluded several higher-risk groups that should not be rewritten as though they were established label language.

Key TRIUMPH-1 Exclusions

Personal or family history of medullary thyroid carcinoma or MEN2.
History of acute or chronic pancreatitis.
Diabetes in the obesity master trial; diabetes was studied separately in TRANSCEND.
Recent weight-loss medication use or prior/planned bariatric surgery.

Additional Precautions

Gallbladder disease or history of gallstones.
Severe gastrointestinal disease, dehydration risk, or delayed gastric emptying.
Pregnancy or breastfeeding, which have not been established as safe uses.
Pre-existing cardiovascular disease or elevated resting heart rate.

Drug Interactions

Insulin, sulfonylureas, and other glucose-lowering medications can increase hypoglycemia risk as glucose control and food intake change. Delayed gastric emptying may also alter the timing of absorption for oral medications.

Regulatory Status

Retatrutide is not FDA approved. In June 2026, FDA stated that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. Lilly states that its investigational retatrutide is legally available only to participants in its clinical trials.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

This was the compound that first got us into peptides and we have longer term N=1 data on it. We currently rank Retatrutide as the top body recomposition peptide available and it has earned that reputation. It offers superior fat loss, appetite control, and better muscle sparing than previous generations. Best results come with disciplined training, high protein intake, and smart supportive peptides such as CJC-1295 no DAC blended with Ipamorelin.

Aside from just weight loss, overall health markers have improved — insulin sensitivity, inflammation is down, and we’ve seen other positive shifts as well. Elite-level tool when used properly. The community is largely impressed with the visible recomp outcomes when run correctly. We have seen some reports of GI sides, but they tend to be manageable with proper titration and support.

From our own experience, the sides started to creep in after roughly 14 weeks and titrating up to 2mg. We cannot get over that dose because the effects have been too great. If you aren't eating enough, you need to step the dose down and this is very important. Recently we have experienced some GI upset and nausea after eating. If you start to develop sides, just roll the dose back down until you find the sweet spot. This is one tool that you want to respect because more does not equate to better and undereating will cost you bone density and muscle. Again, we stress to find the sweet spot of dosing for you and stay there. Standout choice for serious body comp goals.